BIND

BIND Therapeutics, Inc., a clinical-stage nanomedicine company, has teamed up with Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, Inc. The Collaboration has came to engineer Accurins for efficient binding to CD206 positive disease-associated macro phages. View the full release here.